Randomized Clinical Comparison of Everolimus-Eluting SYNERGY® and Biolimus-Eluting BioMatrix NeoFlex® Coronary Stents in Non-Selected Patients With Ischemic Heart Disease
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Everolimus (Primary) ; Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms SORT-OUT VIII
- 24 Apr 2017 Planned End Date changed from 31 Jul 2015 to 31 Dec 2020.
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2015 New trial record